Latest updates for Eli Lilly
Fresh curated links around Eli Lilly are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- <![CDATA[Eli Lilly and Abbisko Announce Drug Development Collaboration]]>
- <![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>
- <![CDATA[Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion ]]>
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>
<![CDATA[Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion ]]>
<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio]]>
Eli Lilly Wins Court Order in Fraud Allegations Against Florida, TN Pharmacy Groups
Eli Lilly, one of the world’s largest pharmaceutical makers, has won a federal court order against leaders of a Tennessee church and Florida and Tennessee-based pharmacy groups, af...
<![CDATA[Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration]]>
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.
<![CDATA[AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly ]]>
Eli Lilly stock extends rally as ACHIEVE-3 trial boosts Foundayo outlook
CVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
Eli Lilly Conspiracy Claim In Compound Drug Row Challenged
A California federal court should toss part of Eli Lilly's third attempt at allegations that a telehealth company, provider group and a now-shuttered pharmacy conspired to falsely...
Lilly buys non-opioid pain drugmaker 4E
It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its...
Here’s What the Street Thinks About Eli Lilly and Company (LLY)
Here’s What the Street is Saying About Eli Lilly and Company (LLY)
<![CDATA[Eli Lilly to Deny 340B Drug Pricing Due to Claims-Data Policy: Report ]]>
Eli Lilly Settles Mounjaro TM Suit Against Seattle Area Clinics
Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismi...
<![CDATA[Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors]]>
Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact
Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabi...
May 26 2026 - Lilly to acquire three vaccine developers for nearly $4 billion
May 26 2026 - Lilly to acquire three vaccine developers for nearly $4 billion admin Tue, 05/26/2026 - 11:55 Lilly keeps pushing forward with deals and pipeline mome...
Eli Lilly issues data sharing ultimatum to 340B hospitals
Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government...
Eli Lilly plans to use its $7.3B cash reserve to fund an "App Store" for biotech scientists after launching a data cente...
Patrick Temple-West / Financial Times: Eli Lilly plans to use its $7.3B cash reserve to fund an “App Store” for biotech scientists after launching a data center with 1,016 Blackwel...
Eli Lilly stock rises after late-stage trial of next-generation weight-loss drug
Eli Lilly shares gained on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.